Affordability focus Akston markets veterinary protein therapeutics designed to be affordable for families, representing an opportunity to position partnerships with animal health distributors and clinics that target value-conscious pet owners.

Vet-focused portfolio With two classes of protein therapies tailored for pets, there is potential to upsell to veterinary hospitals and companion animal clinics seeking diversified biologics portfolios and differentiated pet treatments.

Mid-sized growth Company size (51-200 employees) and revenue in the mid single-digit tens of millions suggest a nimble, scalable partner for collaborative development programs and contract manufacturing opportunities.

Strategic funding Funding of about 47 million combined with moderate revenue indicates readiness for strategic collaborations, co-development deals, and grant-supported R&D initiatives with pharma or biotech allies.

Industry alignment Operating in biotechnology research for veterinary therapies positions Akston to engage with animal health distributors, veterinary networks, and pet care platforms looking to expand advanced therapy options.